By CERBIOS-PHARMA SA
To get in touch with Cerbios-Pharma brings new generic APIs and ADC technology to BIO Boston, simply fill out the form below.
Subscribe to Supplier
Cerbios-Pharma brings new generic APIs and ADC technology to BIO Boston
Lugano, Switzerland: – Swiss-based high-potency API specialist Cerbios-Pharma SA (Cerbios) will showcase its contract development and manufacturing (CDMO) services at the 25th Anniversary BIO International Convention in Boston.
Cerbios will exhibit from Stand 2221 as part of the Swiss Pavilion at the Boston Convention and Exhibition Center (BCEC).
Fully integrated ADCs
“This event provides us with one of the world’s most respected platforms from which to present our Development and cGMP manufacturing services for Antibody Drug Conjugates (ADCs), recombinant protein and chemical Highly Potent API (HPAPI),” declared Matteo Piazza, Business Development Manager for Cerbios.
Cerbios will present the full range of its innovative offers that include a fully integrated Antibody Drug Conjugate (ADC) supply chain (Bioconjugation, SafeBridge Class 4 cytotoxic payloads and recombinant protein) from early stage development up to commercial-scale cGMP manufacturing.
Compressed development time
“Our most attractive promotional offer is the tailored and dedicated service we can provide to all our customers, along with compressed development time and a process that is fully integrated from initial substance development all the way through to fill & finish, thanks to our membership of the PROVEO Alliance,” commented Matteo Piazza. “It’s an offer that is highly attractive, especially for start-ups and mid-sized pharmas and biotechs in the fields of oncology, highly potent compounds and ADCs.”
Highly Potent API (HPAPI) and Cytotoxic Payloads
“Cerbios is proud of being at the forefront of the innovation in Class 4 SafeBridge small molecules HPAPI manufacturing, with a significant cGMP track record in the field’’ stated Mr Piazza. During the Convention Cerbios will promote its GMP manufacturing services to all the companies requiring ADCs payloads and small molecules therapeutics for Oncology.
Cerbios is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacturing of both chemical and biological APIs for its partners world-wide.
Cerbios’ is a global leading supplier of a portfolio of Generic APIs primarily used for the treatment of Respiratory and Dermatological disorders as well as in Oncology.
Exclusive, CDMO services are offered for the development and manufacturing of HPAIs as well as for Biological products including monoclonal antibodies, recombinant proteins, Antibody Drug Conjugates (ADCs) and pharma probiotics.
Cerbios provides full CMC support, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs. Paramount to this is the ability to supply all of the technical documentation and support necessary for a successful registration. Cerbios’ commercial products are marketed worldwide but primarily in Europe, USA, Japan and India.
Since 2015, Cerbios has been a member of the ADC manufacture PROVEO™ consortium, forged with AGC Biologics of Denmark and with Germany’s Oncotec.
PROVEO can offer an ADCs end-to-end service from substance development through manufacturing to fill&finish.
About BIO International 2018
The 25th Anniversary BIO International Convention (BIO) provides a week of intensive networking for biotechnology and pharma leaders to discover new opportunities and promising partnerships. It attracts more than 16,000 delegates involved in a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.
BIO International 2018 returns to Boston MA as a four -day event opening June 4 at the waterfront Boston Convention and Exhibition Center (BCEC). The convention will feature more than 35,000 face-to-face meetings for some 3,100 companies organised using the proprietary BIO One-on-One partnering™ system, as well as hundreds of individual company presentations, a program of world-renowned keynote speakers and some 20 Session Tracks.
A co-located trade show will feature more than 1,800 exhibitors from fields ranging from digital health and diagnostics to bioprocesses.
The event is organized by the Washington DC-based Biotechnology Innovation Organization with more information at: http://convention.bio.org/.